Riedl M, Truyen U, Reese S, Hartmann K
Clinic of Small Animal Medicine, Ludwig-Maximilians-Universitaet of Munich, Veterinaerstrasse 13, Munich 80539, Germany.
Institute for Animal Hygiene and Veterinary Public Health, University of Leipzig, An den Tierkliniken 1, Leipzig 04103, Germany.
Vet Rec. 2015 Dec 12;177(23):597. doi: 10.1136/vr.103271. Epub 2015 Oct 29.
The purpose of this population-based cohort study was to assess current prevalence of antibodies to canine parvovirus (CPV) in adult, healthy dogs, including risk factors associated with lack of antibodies, and reaction to revaccination with a modified live vaccine (MLV). One hundred dogs routinely presented for vaccination were included in the study and vaccinated with a single dose of a combined MLV. Information was collected on signalment, origin, environment, vaccination history and side effects. Prevaccination and postvaccination antibodies were detected by haemagglutination inhibition. Univariate analysis, followed by multivariate logistic regression, was used to investigate association between different variables and presence of antibodies as well as titre increase. Protective CPV antibodies were present in 86.0 per cent of dogs. Intervals of more than four years since the last vaccination and rare contacts with other dogs were determined as main risk factors for the absence of antibodies. An increase in titres only occurred in 17.0 per cent of dogs. Dogs without protective titres before vaccination or with bodyweight <10 kg were more likely to have an adequate titre increase. Based on these findings, antibody status should be determined instead of periodic vaccinations to ensure reliable protection without unnecessary vaccinations in adult dogs.
这项基于人群的队列研究旨在评估成年健康犬中犬细小病毒（CPV）抗体的当前流行率，包括与抗体缺乏相关的风险因素，以及对改良活疫苗（MLV）再次接种的反应。100只常规前来接种疫苗的犬被纳入研究，并接种了单剂量的联合MLV。收集了有关体征、来源、环境、疫苗接种史和副作用的信息。通过血凝抑制检测接种前和接种后的抗体。采用单因素分析，随后进行多因素逻辑回归，以研究不同变量与抗体存在以及滴度增加之间的关联。86.0%的犬存在保护性CPV抗体。自上次接种疫苗以来间隔超过四年以及与其他犬接触稀少被确定为抗体缺乏的主要风险因素。仅17.0%的犬滴度有所增加。接种前无保护性滴度或体重<10 kg的犬更有可能有足够的滴度增加。基于这些发现，应确定抗体状态而非定期接种疫苗，以确保成年犬获得可靠保护且避免不必要的接种。
